Nutratrade srl proposes a new branded product: Prostalife, dry extract of Serenoa repens at 25/45% in fatty acids, oil with 90% in fatty acids obtained through a supercritical CO 2 extraction useful for the treatment and reduction of the symptoms of prostate disorders. The active ingredients contained in the plant are sterols, flavonoids, free fatty acids (oleic, lauric, linoleic, etc.), carotenoids, essential oils, as well as a complex of triglycerides and anthranilic acids, which give the extract rebalancing properties on the hormonal system. , anti-inflammatory and diuretic properties.
Prostalife has been designed for the treatment of diseases of the male urogenital system and in particular for the treatment of benign prostatic hypertrophy (BHP) both in the first stage, in which urinary disorders (dysuria) predominate, and in the second stage, in which increases urinary retention. The effectiveness of Prostalife is conferred by its diuretic property which stimulates the poor urinary flow, typical of this pathology, which leads the bladder to not completely empty, thus allowing the "washing" of the urinary tract and the elimination of bacteria through the urine flow.
The phytocomplex present in Prostalife regulates male hormones in the prostate: it stimulates the estrogen hormone receptors and inhibits progestin receptors. Prostalife thus acts in antagonism with androgens, first of all by inhibiting the enzyme 5-alpha-reductase which transforms testosterone into dihydrotestosterone, a biologically active metabolite of the male sex hormone that stimulates cell proliferation, thus causing hypertrophy of the prostate tissue. The antiestrogenic effect of Prostalife, is able to drastically decrease the estrogen receptors that enhance the hormonal action in the development of BHP.
By contrasting the formation of dihydrotestosterone, Prostalife relieves the symptoms of benign prostatic hypertrophy and in particular decreases the discomfort with urination and preserves the urinary stream without side effects. The antagonistic action on male hormones is therefore the basis of the anti-inflammatory and diuretic properties of Prostalife. This effect is local and does not affect the concentrations of testosterone and of LH and FSH, the hormones produced by the pituitary gland which in turn control the production of male and female hormones. This ensures that the balance of these hormones is preserved.
As an anti-inflammatory, Prostalife acts in a targeted manner by counteracting the action of histamine (the "initiator" molecule of inflammation), inhibiting the enzymes of the cyclooxygenase and 5-lipoxygenase family with consequent inhibition of the synthesis of inflammatory prostaglandins and leukotrienes, thus limiting and prevent inflammation and enlargement of the prostate. Prostalife therefore avoids that it creates volume, compresses the bladder, constricts the urethra, and makes urination difficult and incomplete. Closely related to the anti-inflammatory action, Prostalife also has a marked anti-edema property that leads to the reduction of capillary permeability with consequent reduction of congestion and increase in the volume of prostatic tissues.